Skip to main content
Log in

Evaluation of delayed18F-FDG PET in differential diagnosis for malignant soft-tissue tumors

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

Positron emission tomography (PET) with 2-deoxy-2-[18F]fiuoro-D-glucose (18F-FDG) has been used for the evaluation of soft-tissue tumors. However, the range of accumulation of18F-FDG for malignant soft-tissue lesions overlaps with that of benign lesions. The aim of this study is to investigate the usefulness of delayed18F-FDG PET imaging in the differentiation between malignant and benign soft-tissue tumors.

Methods

Fifty-six patients with soft-tissue tumors underwent whole body18F-FDG PET scan at 1 hour (early scan) and additional scan at 2 hours after injection (delayed scan). The standardized uptake value (SUVmax) of the tumor was determined, and the retention index (RI) was defined as the ratio of the increase in SUVmax between early and delayed scans to the SUVmax in the early scan. Surgical resection with histopathologic analysis confirmed the diagnosis.

Results

Histological examination proved 19 of 56 patients to have malignant soft-tissue tumors and the rest benign ones. In the scans of all 56 patients, there was a statistically significant difference in the SUVmax between malignant and benign lesions in the early scan (5.50 ± 5.32 and 3.10 ± 2.64, respectively, p < 0.05) and in the delayed scan (5.95 ± 6.40 and 3.23 ± 3.20, respectively, p < 0.05). The mean RI was not significantly different between malignant and benign soft-tissue tumors (0.94 ± 23.04 and -2.03 ± 25.33, respectively).

Conclusions

In the current patient population, no significant difference in the RI was found between malignant and benign soft-tissue lesions. Although the mean SUVmax in the delayed scan for malignant soft-tissue tumors was significantly higher than that for benign ones, there was a marked overlap. The delayed18F-FDG PET scan may have limited capability to differentiate malignant soft-tissue tumors from benign ones.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Strauss LG, Conti PS. The applications of PET in clinical oncology.J Nucl Med 1991; 32 (4): 623–648; discussion 49-50.

    PubMed  CAS  Google Scholar 

  2. Aoki J, Watanabe H, Shinozaki T, Takagishi K, Tokunaga M, Koyama Y, et al. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses.Skeletal Radiol 2003; 32 (3): 133–138.

    PubMed  CAS  Google Scholar 

  3. Kern KA, Brunetti A, Norton JA, Chang AE, Malawer M, Lack E, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET.J Nucl Med 1988; 29 (2): 181–186.

    PubMed  CAS  Google Scholar 

  4. Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual time point fluorine-18 fluorodeoxy-glucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck.Eur J Nucl Med 1999; 26 (10): 1345–1348.

    Article  PubMed  CAS  Google Scholar 

  5. Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection.Eur J Nucl Med 2001; 28 (6): 696–703.

    Article  PubMed  CAS  Google Scholar 

  6. Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point18F-FDG PET for the evaluation of pulmonary nodules.J Nucl Med 2002; 43 (7): 871–875.

    PubMed  Google Scholar 

  7. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, et al. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.Cancer 2000 15; 89 (12): 2547–2554.

    Article  PubMed  CAS  Google Scholar 

  8. Alenius S, Ruotsalainen U. Bayesian image reconstruction for emission tomography based on median root prior.Eur J Nucl Med 1997; 24 (3): 258–265.

    PubMed  CAS  Google Scholar 

  9. Adler LP, Blair HF, Makley JT, Williams RP, Joyce MJ, Leisure G, et al. Noninvasive grading of musculoskeletal tumors using PET.J Nucl Med 1991; 32 (8): 1508–1512.

    PubMed  CAS  Google Scholar 

  10. Griffeth LK, Dehdashti F, McGuire AH, McGuire DJ, Perry DJ, Moerlein SM, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-d-glucose.Radiology 1992; 182 (1): 185–194.

    PubMed  CAS  Google Scholar 

  11. Hamada K, Ueda T, Higuchi I, Inoue A, Tamai N, Myoi A, et al. Peripheral nerve schwannoma: two cases exhibiting increased FDG uptake in early and delayed PET imaging.Skeletal Radiol 2005; 34 (1): 52–57.

    Article  PubMed  Google Scholar 

  12. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O’ Doherty MJ, Smith MA. A PET study of18FDG uptake in soft tissue masses.Eur J Nucl Med 1999; 26 (1): 22–30.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Enomoto, K., Higuchi, I., Hatazawa, J. et al. Evaluation of delayed18F-FDG PET in differential diagnosis for malignant soft-tissue tumors. Ann Nucl Med 20, 671–675 (2006). https://doi.org/10.1007/BF02984678

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02984678

Key words

Navigation